Pasatru (garetosmab-grts)
Fibrodysplasia Ossificans Progressiva (FOP) Agents Intravenous Vial (Ml)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Generic name: garetosmab-grts
Drug class: Fibrodysplasia Ossificans Progressiva (FOP) Agents
Therapeutic class: Locomotor System
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Pasatru
Indications
The following indications are listed for Pasatru:
- Fibrodysplasia Ossificans Progressiva
Also known as: Munchmeyer Disease, Progressive Myositis Ossificans.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Pasatru 300 Mg/5 Ml Vial | Maintenance | Infuse 10 mg/kg over 60 minute(s) by intravenous route every 4 weeks. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
Igg Antibodies And Derivatives/Efgartigimod-Alfa
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Efgartigimod-alfa binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of efgartigimod-alfa states that efgartigimod-alfa should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, efgartigimod-alfa should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with efgartigimod-alfa have not been performed. Efgartigimod-alfa may decrease concentrations of compounds that bind to the human FcRn.(3)
Igg Antibodies And Derivatives/Nipocalimab-Aahu
SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Nipocalimab-aahu binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medicines that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of nipocalimab-aahu states that nipocalimab-aahu should not be combined with long-term use of FcRn-binding medications. If the medication is essential for the patient, nipocalimab-aahu should be discontinued.(3)
DISCUSSION: Clinical drug interaction studies with nipocalimab-aahu have not been performed. Nipocalimab-aahu may decrease concentrations of compounds that bind to the human FcRn.(3)
Moderate Interaction: Assess the risk to the patient and take action as needed.
Igg Antibodies And Derivatives/Rozanolixizumab-Noli
SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.
MECHANISM OF ACTION: The neonatal Fc receptor (FcRn) prevents catabolism and mediates recycling of IgG and albumin, which leads to their long persistence in the body.(1,2) Rozanolixizumab-noli binds to FcRn and may decrease systemic exposure of other ligands of FcRn, like immunoglobulins and IgG-based antibodies.(3)
CLINICAL EFFECTS: The effectiveness of medications that bind to FcRn may be decreased.(3)
PREDISPOSING FACTORS: None determined.
PATIENT MANAGEMENT: The manufacturer of rozanolixizumab-noli states that concurrent use with medications that bind to the human neonatal Fc receptor (FcRn) should be closely monitored for reduced effectiveness of these medications. If long-term use of such medications is essential for the patient, consider discontinuing rozanolixizumab-noli and use alternative therapies.(3)
DISCUSSION: Clinical drug interaction studies with rozanolixizumab-noli have not been performed. Rozanolixizumab-noli may decrease concentrations of compounds that bind to the human FcRn.(3)
Contraindications
There is no enhanced messaging for this drug.
- Lactation
- Pregnancy
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
More Frequent
- Abscess
Rare or Very Rare
- Skin and skin structure infection
More Frequent
- Acne vulgaris
- Epistaxis
- Hirsutism
- Madarosis of eyelid
- Oral ulcer
Less Frequent
- Cellulitis
- Folliculitis
- Paronychia
- Skin rash
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Fibrodysplasia ossificans progressiva | ||
| M61.1 | ICD10CM | Myositis ossificans progressiva |
| M61.10 | ICD10CM | Myositis ossificans progressiva, unspecified site |
| M61.111 | ICD10CM | Myositis ossificans progressiva, right shoulder |
| M61.112 | ICD10CM | Myositis ossificans progressiva, left shoulder |
| M61.119 | ICD10CM | Myositis ossificans progressiva, unspecified shoulder |
| M61.121 | ICD10CM | Myositis ossificans progressiva, right upper arm |
| M61.122 | ICD10CM | Myositis ossificans progressiva, left upper arm |
| M61.129 | ICD10CM | Myositis ossificans progressiva, unspecified upper arm |
| M61.131 | ICD10CM | Myositis ossificans progressiva, right forearm |
| M61.132 | ICD10CM | Myositis ossificans progressiva, left forearm |
| M61.139 | ICD10CM | Myositis ossificans progressiva, unspecified forearm |
| M61.141 | ICD10CM | Myositis ossificans progressiva, right hand |
| M61.142 | ICD10CM | Myositis ossificans progressiva, left hand |
| M61.143 | ICD10CM | Myositis ossificans progressiva, unspecified hand |
| M61.144 | ICD10CM | Myositis ossificans progressiva, right finger(s) |
| M61.145 | ICD10CM | Myositis ossificans progressiva, left finger(s) |
| M61.146 | ICD10CM | Myositis ossificans progressiva, unspecified finger(s) |
| M61.151 | ICD10CM | Myositis ossificans progressiva, right thigh |
| M61.152 | ICD10CM | Myositis ossificans progressiva, left thigh |
| M61.159 | ICD10CM | Myositis ossificans progressiva, unspecified thigh |
| M61.161 | ICD10CM | Myositis ossificans progressiva, right lower leg |
| M61.162 | ICD10CM | Myositis ossificans progressiva, left lower leg |
| M61.169 | ICD10CM | Myositis ossificans progressiva, unspecified lower leg |
| M61.171 | ICD10CM | Myositis ossificans progressiva, right ankle |
| M61.172 | ICD10CM | Myositis ossificans progressiva, left ankle |
| M61.173 | ICD10CM | Myositis ossificans progressiva, unspecified ankle |
| M61.174 | ICD10CM | Myositis ossificans progressiva, right foot |
| M61.175 | ICD10CM | Myositis ossificans progressiva, left foot |
| M61.176 | ICD10CM | Myositis ossificans progressiva, unspecified foot |
| M61.177 | ICD10CM | Myositis ossificans progressiva, right toe(s) |
| M61.178 | ICD10CM | Myositis ossificans progressiva, left toe(s) |
| M61.179 | ICD10CM | Myositis ossificans progressiva, unspecified toe(s) |
| M61.18 | ICD10CM | Myositis ossificans progressiva, other site |
| M61.19 | ICD10CM | Myositis ossificans progressiva, multiple sites |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.